key: cord-0884040-2rhhw3sx
authors: Patrì, Angela; Fabbrocini, Gabriella
title: Hydroxychloroquine and ivermectin: a synergistic combination for COVID-19 chemoprophylaxis and/or treatment?
date: 2020-04-10
journal: J Am Acad Dermatol
DOI: 10.1016/j.jaad.2020.04.017
sha: 6e727153a04d95b4a266155bd00fda50b50997cf
doc_id: 884040
cord_uid: 2rhhw3sx

nan

authors hypothesized that such results were likely due to the inhibition of IMPα/β1-mediated nuclear import of viral proteins, as shown for other RNA viruses. 4 However, no study with ivermectin in vivo has been already conducted. Basing on all such evidence, we hypothesize that HCQ and ivermectin could act in a consequential and synergistic manner. Indeed, HCQ would behave as a first level barrier by inhibiting the entry of the virus into the host cell, while ivermectin could reduce viral replication if the virus could get in, strengthening HCQ antiviral effects. HCQ is cheap to produce, and safe if monitored properly. Ivermectin seems to be safe and well tolerated with no serious drug-related adverse events. 5 Moreover, such two drugs dot not seem to interact between them. However, no studies, neither in vitro nor in vivo, have been conducted on the combined effect of HCQ and ivermectin on SARS-CoV-2 infection. Ours is only a hypothesis and a suggestion, but if not now, when should researchers share ideas?

COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus

Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivo

The FDA approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro

Treatment of Human Scabies with Oral Ivermectin. Eczematous Eruptions as a New Non-Reported Adverse Event